FDA Accepts Supplement Application for ELIGARD Kit by TOLMAR
The FDA has accepted a supplemental application for the ELIGARD Kit, which contains leuprolide acetate.
Asset / Drug
Drug and asset intelligence for TOLMAR with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Hormonal Therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.